Donald Staines

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Source: investinme.org

Professor Donald R. Staines, MBBS, MPH, FAFPHM, FAFOEM, is a Clinical Professor at Menzies Health Institute Queensland and the co-director (alongside Sonya Marshall-Gradisnik) of the National Centre for Neuroimmunology and Emerging Diseases (NCNED) at Griffith University in Queensland in north-eastern Australia.[1] His research team is working towards discovery of diagnostic tools and treatments for chronic fatigue syndrome.[2]

International Consensus Criteria[edit | edit source]

Staines is one of the authors of the 2011 case definition, International Consensus Criteria.[3]

Diagnostic test[edit | edit source]

In February 2016 the research team led by Donald Staines and Sonya Marshall-Gradisnik announced it had created a diagnostic test for the disease using CD8 T cells.[4] They have been awarded a $4-million grant to be administered during the next five years that will enable them to continue research into developing a diagnostic test for ME/CFS.[5]

Open Letters to The Lancet[edit | edit source]

Three open letters to the editor of The Lancet urged the editor to commission a fully independent review of the PACE trial, which the journal had published in 2011. In 2016, Dr. Staines, along with 41 colleagues in the ME/CFS field, signed the second letter. In June 2018, Dr. Staines signed the third letter, this time along with approximately 100 colleagues.

Notable studies[edit | edit source]

  • 2011, Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[6] - (Full Text)
  • 2012, The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[7] - (Full Text)
  • 2014, Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[8] - (Full Text)
  • 2014, The Role of Adaptive and Innate Immune Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[9] - (Full Text)
  • 2014, The role of clinical guidelines for chronic fatigue syndrome/myalgic encephalomyelitis in research settings[10] - (Abstract)
  • 2014, Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[11] - (Full Text)
  • 2015, A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients[12]
  • 2015, Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients[13] - (Abstract)
  • 2015, Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[14] - (Full Text)
  • 2015, Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients[15] - (Full Text)
  • 2015, Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[16] - (Full Text)
  • 2015, Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[17] - (Full Text)
  • 2015, Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[18]
  • 2016, Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients[19] - (Full Text)
  • 2016, A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[20] - (Abstract)
  • 2016, Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study[21] - (Full Text)
  • 2016, Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison[22] - (Full Text)
  • 2016, ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[23] - (Full Text)
  • 2016, Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome[24] - (Full Text)
  • 2017, Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review[25] - (Full Text)
  • 2017, Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels[26] - (Full Text)
  • 2017, Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients[27] - (Full Text)
  • 2018, Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis[28] - (Full text)
  • 2018, Brain function characteristics of chronic fatigue syndrome: A task fMRI study[29] - (Full Text)
  • 2018, A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)[30] - (Abstract)
  • 2018, A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis[31] - (Full text)
  • 2018, Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation[32] - (Full Text)
  • 2018, Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation[33] - (Abstract)
  • 2018, Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome[34] - (Full Text)
  • 2018, Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients[35] - (Full Text)
  • 2019, Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study[36] - (Full text)
  • 2019, Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients[37] - (Full text)
  • 2019, A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)[38] - (Full text)
  • 2019, Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients[39] - (Abstract)
  • 2019, Intra brainstem connectivity is impaired in chronic fatigue syndrome[40] - (Full text)
  • 2019, Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients[41] - (Full text)
  • 2020, Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study[42] - (Full text)
  • 2020, Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans[43] - (Full text)
  • 2021, Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[44] - (Full text)
  • 2021, Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment[45] - (Full text)

Talks and interviews[edit | edit source]

Learn more[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ "National Centre for Neuroimmunology and Emerging Diseases". griffith.edu.au. Retrieved November 14, 2019.
  2. ↑ "Coast team zeroing in on CFS test". goldcoastbulletin.com.au. December 1, 2016. Retrieved April 26, 2019.
  3. ↑ Carruthers, Bruce M.; van de Sande, Marjorie I.; De Meirleir, Kenny L.; Klimas, Nancy G.; Broderick, Gordon; Mitchell, Terry; Staines, Donald; Powles, A.C. Peter; Speight, Nigel; Vallings, Rosamund; Bateman, Lucinda; Baumgarten-Austrheim, Barbara; Bell, David; Carlo-Stella, Nicoletta; Chia, John; Darragh, Austin; Jo, Daehyun; Lewis, Donald; Light, Alan; Marshall-Gradisnik, Sonya; Mena, Ismael; Mikovits, Judy; Miwa, Kunihisa; Murovska, Modra; Pall, Martin; Stevens, Staci (August 22, 2011). "Myalgic encephalomyelitis: International Consensus Criteria". Journal of Internal Medicine. 270 (4): 327–338. doi:10.1111/j.1365-2796.2011.02428.x. ISSN 0954-6820. PMC 3427890. PMID 21777306.
  4. ↑ Australian scientists make breakthrough in Chronic Fatigue Syndrome testing, ABC News (Australia), 29 February 2016
  5. ↑ "Coast team zeroing in on CFS test". goldcoastbulletin.com.au. December 1, 2016. Retrieved April 26, 2019.
  6. ↑ Brenu, EW; van Driel, ML; Staines, DR; Ashton, KJ; Ramos, SB; Keane, J; Klimas, NG; Marshall-Gradisnik, SM (2011). "Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Journal of Translational Medicine. 9 (81). doi:10.1186/1479-5876-9-81.
  7. ↑ Brenu, Ekua W; van Driel, Mieke L; Staines, Donald R; Kreijkamp-Kaspers, Sanne; Hardcastle, Sharni L; Marshall-Gradisnik, Sonya M (2012). "The Effects of Influenza Vaccination on Immune Function in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis" (PDF). International Journal of Clinical Medicine. 3 (6): 544-551. doi:10.4236/ijcm.2012.36098.
  8. ↑ Huth, Teilah K.; Brenu, Ekua; Nguyen, Thao; Hardcastle, Sharni L.; Johnston, Samantha; Ramos, Sandra; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2014). "Characterization of Natural Killer Cell Phenotypes in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Journal of Clinical & Cellular Immunology. 5 (3). doi:10.4172/2155-9899.1000223.
  9. ↑ Brenu, EW; Huth, TK; Hardcastle, SL; Fuller, K; Kaur, M; Johnston, S; Ramos, S; Staines, D; Marshall-Gradisnik, S (2014). "The Role of adaptive and innate immune cells in chronic fatigue syndrome/myalgic encephalomyelitis". International Immunology. 26 (4): 233–42. doi:10.1093/intimm/dxt068. PMID 24343819.
  10. ↑ Johnston, S.C.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (January 2, 2014). "The role of clinical guidelines for chronic fatigue syndrome/myalgic encephalomyelitis in research settings". Fatigue: Biomedicine, Health & Behavior. 2 (1): 28–39. doi:10.1080/21641846.2013.860779. ISSN 2164-1846.
  11. ↑ Hardcastle, Sharni L.; Brenu, Ekua W.; Johnston, Samantha; Nguyen, Thao; Huth, Teilah K.; Kaur, Manprit; Ramos, Sandra; Salajegheh, Ali; Staines, Donald R.; Marshall-Gradisnik, Sonya (2014). "Analysis of the Relationship between Immune Dysfunction and Symptom Severity in Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)". Journal of Clinical & Cellular Immunology. 5 (190). doi:10.4172/2155-9899.1000190.
  12. ↑ Wong, Naomi; Nguyen, Thao; Brenu, Ekua Weba; Broadley, Simon; Staines, Donald; Marshall-Gradisnik, Sonya (2015). "A Comparison of Cytokine Profiles of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis Patients". International Journal of Clinical Medicine. 6 (10): 769–783. doi:10.4236/ijcm.2015.610103.
  13. ↑ Armstrong, Christopher W.; McGregor, Neil R.; Lewis, Donald P.; Butt, Henry L.; Gooley, Paul R. (2015). "Metabolic profiling reveals anomalous energy metabolism and oxidative stress pathways in chronic fatigue syndrome patients". Metabolomics. 11 (6): 1626–1639. doi:10.1007/s11306-015-0816-5.
  14. ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015). "Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". International Journal of Medical Sciences. 12 (10): 764–772. doi:10.7150/ijms.12399.
  15. ↑ Marshall-Gradisnik, Sonya M.; Smith, Peter; Brenu, Ekua W.; Nilius, Bernd; Ramos, Sandra B.; Staines, Donald R. (2015). "Examination of Single Nucleotide Polymorphisms (SNPs) in Transient Receptor Potential (TRP) Ion Channels in Chronic Fatigue Syndrome Patients". Immunology and Immunogenetics Insights. 2015 (7): 1–6. doi:10.4137/III.S25147.
  16. ↑ Hardcastle, SL; Brenu, EW; Johnston, S; Nguyen, T; Huth, T; Wong, N; Ramos, S; Staines, DR; Marshall-Gradisnik, SM (2015). "Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)". BMC Immunology. 16 (35). doi:10.1186/s12865-015-0101-4.
  17. ↑ Hardcastle, Sharni Lee; Brenu, Ekua Weba; Johnston, Samantha; Nguyen, Thao; Huth, Teilah; Ramos, Sandra; Staines, Donald; Marshall-Gradisnik, Sonya (2015). "Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 13 (299). doi:10.1186/s12967-015-0653-3.
  18. ↑ Peterson, D; Brenu, EW; Gottschalk, G; Ramos, Sandra B; Nguyen, T; Staines, D; Marshall-Gradisnik, S (2015). "Cytokines in the Cerebrospinal Fluids of Patients with Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Mediators of Inflammation. 2015. doi:10.1155/2015/929720.
  19. ↑ Huth, T.K.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S.M. (2016). "Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients". Gene Regulation and Systems Biology. 10: 43–49. doi:10.4137/GRSB.S39861.
  20. ↑ Collatz, Ansel; Johnston, Samantha C.; Staines, Donald R.; Marshall-Gradisnik, Sonya M. (2016). "A Systematic Review of Drug Therapies for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". Clinical Therapeutics. 38 (6): 1263-1271.e9. doi:10.1016/j.clinthera.2016.04.038. PMID 27229907.
  21. ↑ Shan, Zack Y.; Kwiatek, Richard; Burnet, Richard; Del Fante, Peter; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2016). "Progressive brain changes in patients with chronic fatigue syndrome: A longitudinal MRI study". Journal of Magnetic Resonance Imaging. 44: 1301–1311. doi:10.1002/jmri.25283.
  22. ↑ Ramos, S; Brenu, E; Broadley, S; Kwiatek, R; Ng, J; Nguyen, T; Freeman, S; Staines, D; Marshall-Gradisnik, S (March 20, 2016). "Regulatory T, natural killer T and γδ T cells in multiple sclerosis and chronic fatigue syndrome/myalgic encephalomyelitis: a comparison". Asian Pac J Allergy Immunol. doi:10.12932/AP0733.
  23. ↑ Huth, Teilah K.; Staines, Donald; Marshall-Gradisnik, Sonya (2016). "ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/− natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Journal of Translational Medicine. 14 (97). doi:10.1186/s12967-016-0859-z.
  24. ↑ Marshall-Gradisnik, Sonya M.; Huth, Teilah; Chacko, Anu; Johnston, Samantha; Smith, Peter; Staines, Donald R. (2016). "Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome". The Application of Clinical Genetics. 9: 39–47. doi:10.2147/TACG.S99405.
  25. ↑ Campagnolo, N.; Johnston, S.; Collatz, A.; Staines, D.; Marshall-Gradisnik, S. (January 22, 2017). "Dietary and nutrition interventions for the therapeutic treatment of chronic fatigue syndrome/myalgic encephalomyelitis: a systematic review". Journal of Human Nutrition and Dietetics. 30 (3): 247–259. doi:10.1111/jhn.12435. ISSN 0952-3871. PMID 28111818.
  26. ↑ Nguyen, T.; Hardcastle, S.; Clarke, L.; Smith, P.; Staines, D.; Marshall-Gradisnik, S. (2017). "Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels". Clinical and Experimental Immunology. 187 (2): 284–293. doi:10.1111/cei.12882.
  27. ↑ Nguyen, T.; Johnston, S.; Chacko, A.; Gibson, D.; Cepon, J.; Smith, D.; Staines, D.; Marshall-Gradisnik, S. (2017). "Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients". Asian Pac J Allergy Immunol. 35 (2): 75-81. doi:10.12932/AP0771.
  28. ↑ Marshall-Gradisnik, Sonya; Fretel, Marshall; Eaton, Natalie; Cabanas, Helene; Balinas, Cassandra; Gopalan, Vinod; Petersen, Daniel; Passmore, Rachel; Tang, Kevin; Haque, Mazhar; Lam, Alfred; Staines, Donald (May 31, 2018). "Decreased Expression of TRPM3 and mAChRM3 in the Small Intestine in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis". International Journal of Clinical Medicine. 09 (05): 467. doi:10.4236/ijcm.2018.95040.
  29. ↑ Shan, Zack Y.; Finegan, Kevin; Bhuta, Sandeep; Ireland, Timothy; Staines, Donald R.; Marshall‐Gradisnik, Sonya; Barnden, Leighton R. (2018). "Brain function characteristics of chronic fatigue syndrome: A task fMRI study". NeuroImage: Clinical. 19: 279–286. doi:10.1016/j.nicl.2018.04.025.
  30. ↑ Corbitt, M; Campagnolo, N; Staines, D; Marshall-Gradisnik, S (2018). "A Systematic Review of Probiotic Interventions for Gastrointestinal Symptoms and Irritable Bowel Syndrome in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)". Probiotics Antimicrob Proteins. doi:10.1007/s12602-018-9397-8.
  31. ↑ Du Preez, S.; Corbitt, M.; Cabanas, H.; Eaton, N.; Staines, D.; Marshall-Gradisnik, S. (December 20, 2018). "A systematic review of enteric dysbiosis in chronic fatigue syndrome/myalgic encephalomyelitis". Systematic Reviews. 7 (1): 241. doi:10.1186/s13643-018-0909-0. ISSN 2046-4053. PMID 30572962.
  32. ↑ Eaton, Natalie; Cabanas, Hélène; Balinas, Cassandra; Klein, Anne; Staines, Donald R.; Marshall-Gradisnik, Sonya (2018). "Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation". BMC Pharmacology & Toxicology. 19 (12). doi:10.1186/s40360-018-0203-8. PMID 29587879.
  33. ↑ Nguyen, T.; Staines, D.; Johnston, S.; Marshall-Gradisnik, S. (July 2018). "Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation". Asian Pac J Allergy Immunol. doi:10.12932/AP-011117-0188.
  34. ↑ Barnden, Leighton R.; Shan, Zack Y.; Staines, Donald R.; Marshall-Gradisnik, Sonya; Finegan, Kevin; Ireland, Timothy; Bhuta, Sandeep (2018). "Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome". NeuroImage: Clinical. 20: 102–109. doi:10.1016/j.nicl.2018.07.011.
  35. ↑ Cabanas, Hélène; Muraki, Katsuhiko; Eaton, Natalie; Balinas, Cassandra; Staines, Donald; Marshall-Gradisnik, Sonya (August 14, 2018). "Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients". Molecular Medicine. 24 (1). doi:10.1186/s10020-018-0046-1. ISSN 1076-1551.
  36. ↑ Słomko, Joanna; Newton, Julia L; Kujawski, Sławomir; Tafil-Klawe, Małgorzata; Klawe, Jacek; Staines, Donald; Marshall-Gradisnik, Sonya; Zalewski, Pawel (March 2019). "Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study". BMJ Open. 9 (3): e023955. doi:10.1136/bmjopen-2018-023955. ISSN 2044-6055. PMID 30850404.
  37. ↑ Cabanas, H.; Muraki, K.; Balinas, C.; Eaton-Fitch, N.; Staines, D.; Marshall-Gradisnik, S. (December 2019). "Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients". Molecular Medicine. 25 (1). doi:10.1186/s10020-019-0083-4. ISSN 1076-1551.
  38. ↑ Corbitt, Matthew; Eaton-Fitch, Natalie; Staines, Donald; Cabanas, Hélène; Marshall-Gradisnik, Sonya (December 2019). "A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID)". BMC Neurology. 19 (1). doi:10.1186/s12883-019-1433-0. ISSN 1471-2377. PMID 31445522.
  39. ↑ Cabanas, Helene; Muraki, Katsuhiko; Staines, Donald; Marshall-Gradisnik, Sonya (October 14, 2019). "Naltrexone restores impaired transient receptor potential melastatin 3 ion channel function in natural killer cells from myalgic encephalomyelitis/chronic fatigue syndrome patients". Frontiers in Immunology. doi:10.3389/fimmu.2019.02545.
  40. ↑ Barnden, Leighton R; Shan, Zack Y; Staines, Donald R; Marshall-Gradisnik, Sonya; Finegan, Kevin; Ireland, Timothy; Bhuta, Sandeep (2019). "Intra brainstem connectivity is impaired in chronic fatigue syndrome". NeuroImage: Clinical. 24: 102045. doi:10.1016/j.nicl.2019.102045.
  41. ↑ Balinas, Cassandra; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (December 3, 2019). "Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients". Journal of Translational Medicine. 17 (1): 401. doi:10.1186/s12967-019-02155-4. ISSN 1479-5876. PMC 6891975. PMID 31796045.
  42. ↑ Eaton-Fitch, N.; Johnston, S. C.; Zalewski, P.; Staines, D.; Marshall-Gradisnik, S. (January 22, 2020). "Health-related quality of life in patients with myalgic encephalomyelitis/chronic fatigue syndrome: an Australian cross-sectional study". Quality of Life Research. doi:10.1007/s11136-019-02411-6. ISSN 0962-9343.
  43. ↑ Thapaliya, Kiran; Marshall-Gradisnik, Sonya; Staines, Don; Barnden, Leighton (2020). "Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans". NeuroImage: Clinical. 28: 102366. doi:10.1016/j.nicl.2020.102366. PMC 7417892. PMID 32777701.
  44. ↑ Maksoud, Rebekah; Eaton-Fitch, Natalie; Matula, Michael; Cabanas, Hélène; Staines, Donald; Marshall-Gradisnik, Sonya (May 2021). "Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". Healthcare. 9 (5): 568. doi:10.3390/healthcare9050568.
  45. ↑ Cabanas, Helene; Muraki, Katsuhiko; Eaton-Fitch, Natalie; Staines, Donald Ross; Marshall-Gradisnik, Sonya (2021). "Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment". Frontiers in Immunology. 12: 687806. doi:10.3389/fimmu.2021.687806. ISSN 1664-3224. PMC 8313851. PMID 34326841.
  46. ↑ 46.0 46.1 "UK Charity for Myalgic Encephalomyelitis Centre of Excellence for ME Blog". investinme.org. Retrieved April 26, 2019.
  47. ↑ "IIMEC14 14th Invest in ME Reseaerch International ME Conference 2019". Invest in ME Research. Retrieved February 26, 2020.
Retrieved from "https://me-pedia.org/w/index.php?title=Donald_Staines&oldid=241624"